Organon & Co. Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
Organon & Co. (OGN) reported Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense of $12.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Interest Expense
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense · last filed 2026-02-24
- Organon & Co. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2025 was $12.00M.
- Organon & Co. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2024 was -$15.00M, a 600.00% decline from fiscal 2023.
- Organon & Co. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2023 was $3.00M.
- Organon & Co. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2020 was $11.00M.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 12 month |
|---|---|
| 2025-12-31 | $12.00M 10-K · filed 2026-02-24 |
| 2024-12-31 | -$15.00M 10-K · filed 2026-02-24 |
| 2023-12-31 | $3.00M 10-K · filed 2026-02-24 |
| 2020-12-31 | $11.00M 10-K · filed 2023-02-27 |
| 2019-12-31 | -$48.00M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |